Q3 Earnings Estimate for Prenetics Global Issued By Sidoti

Prenetics Global Limited (NASDAQ:PRE) – Sidoti issued their Q3 2026 earnings per share (EPS) estimates for shares of Prenetics Global in a report issued on Monday, June 22nd. Sidoti analyst A. Hantman expects that the company will post earnings per share of ($0.48) for the quarter. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.77) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.07) EPS, Q2 2027 earnings at $0.00 EPS, Q3 2027 earnings at $0.75 EPS, Q4 2027 earnings at $1.21 EPS and FY2027 earnings at $1.89 EPS.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.07). The business had revenue of $35.95 million during the quarter, compared to analysts’ expectations of $36.00 million. Prenetics Global had a negative return on equity of 20.33% and a negative net margin of 62.45%.

Several other equities analysts have also recently issued reports on the stock. Benchmark started coverage on shares of Prenetics Global in a research note on Tuesday, June 16th. They set a “buy” rating and a $30.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Prenetics Global in a report on Tuesday, April 21st. Finally, Lake Street Capital started coverage on shares of Prenetics Global in a report on Monday, March 16th. They issued a “buy” rating and a $29.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $31.75.

Prenetics Global Price Performance

Prenetics Global stock opened at $19.92 on Wednesday. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The business’s fifty day moving average is $18.41 and its 200 day moving average is $18.17. The stock has a market capitalization of $336.05 million, a PE ratio of -4.35 and a beta of 0.24.

Hedge Funds Weigh In On Prenetics Global

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in shares of Prenetics Global during the 4th quarter valued at about $1,302,000. 683 Capital Management LLC bought a new position in shares of Prenetics Global during the 4th quarter valued at approximately $1,181,000. Millennium Management LLC purchased a new stake in Prenetics Global in the 4th quarter worth approximately $810,000. Marshall Wace LLP purchased a new stake in Prenetics Global in the 4th quarter worth approximately $788,000. Finally, Goldman Sachs Group Inc. purchased a new stake in Prenetics Global in the 4th quarter worth approximately $665,000. 25.01% of the stock is owned by institutional investors.

Prenetics Global announced that its board has approved a share repurchase program on Friday, March 6th that permits the company to buyback $40.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 15.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s management believes its shares are undervalued.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.